Clinical trials in Mainz – page 23

604 clinical trials in Mainz, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Mainz at a glance

604

clinical trials

Research sites1

Quick filters

604 trials in Mainz

Open in trial search

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Secondary progressive multiple sclerosis+1

Not yet recruiting

Study on the Safety and Effects of YTB323 and Drug Combination in Patients with Progressive Multiple Sclerosis

Registered drugNo placebo

Study on the Safety and Effects of YTB323 and Drug Combination in Patients with Progressive Multiple Sclerosis

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Cyclophosphamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Relapsing multiple sclerosis

Not yet recruiting

Study on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment

Registered drugNo placebo

Study on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Cyclophosphamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Azathioprine
Sponsor:Novartis Pharma AG

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Gastrooesophageal cancer

Not yet recruiting

Study of Bemarituzumab with Irinotecan, Paclitaxel, Ramucirumab, or Trifluridine/Tipiracil for Advanced Stomach or Gastroesophageal Cancer in Patients After Chemotherapy

Registered drugNo placebo

Study of Bemarituzumab with Irinotecan, Paclitaxel, Ramucirumab, or Trifluridine/Tipiracil for Advanced Stomach or Gastroesophageal Cancer in Patients After Chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bemarituzumab
Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Chronic kidney disease-associated pruritus

Not yet recruiting

Evaluation of MC2-25 Cream for Itching in Patients with Chronic Kidney Disease-associated Pruritus

Investigational

Evaluation of MC2-25 Cream for Itching in Patients with Chronic Kidney Disease-associated Pruritus

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Mc2 Therapeutics Limited

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:GPOH gGmbH

Contact Research Centre

Device dependence

Not yet recruiting

Study on Renaparin for Improving Kidney Function in Transplant Patients with End-Stage Renal Disease from Deceased Donors

InvestigationalNo placebo

Study on Renaparin for Improving Kidney Function in Transplant Patients with End-Stage Renal Disease from Deceased Donors

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Corline Heparin Conjugate
Sponsor:Corline Biomedical AB

Contact Research Centre

Major depression+2

Not yet recruiting

Study on Enhanced Treatment for Schizophrenia, Depression, and Bipolar Disorder Using Esketamine, Bupropion, and Quetiapine for Patients with Initial Treatment Failure

Registered drugNo placebo

Study on Enhanced Treatment for Schizophrenia, Depression, and Bipolar Disorder Using Esketamine, Bupropion, and Quetiapine for Patients with Initial Treatment Failure

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Clozapine
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Cytarabine
Sponsor:GPOH gGmbH

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Mainz

What the registry says about research in the country

01 Infectious Disease Prevention

Groundbreaking trials focusing on viral infections including studies of vaccines against Respiratory Syncytial Virus, Herpes Zoster, and Cytomegalovirus. Research aims to evaluate vaccine efficacy and immune response in different age groups.

RSV and hMPV Prevention
Herpes Zoster Protection
CMV Vaccine Development

Special attention is given to protecting vulnerable populations, including older adults and those at increased risk.

02 Oncology Research

Innovative clinical trials targeting various forms of cancer, including studies on breast cancer, pancreatic cancer, and multiple myeloma. Research focuses on novel therapeutic approaches and combination treatments.

Advanced Breast Cancer Therapy
Gastric Cancer Treatment
Lymphoma Management

Emphasis on personalized medicine approaches and targeted therapies for better patient outcomes.

03 Chronic Disease Management

Comprehensive studies addressing respiratory conditions, autoimmune disorders, and metabolic diseases. Research includes treatments for asthma, multiple sclerosis, and obesity.

Pulmonary Hypertension
Chronic Kidney Disease
Autoimmune Conditions

Focus on developing long-term treatment solutions and improving quality of life for patients.

Back to Germany All countries